Uraemic toxins induce proximal tubular injury via organic anion transporter 1‐mediated uptake
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A direct effect of uraemic toxins in promoting progression of chronic renal disease has not been established. In this study, we investigated the toxic effects of organic anions which characteristically appeared in the patients with progressive renal disease on renal proximal tubular cells expressing human organic anion transporter (hOAT) 1. A renal proximal tubular cell line, opossum kidney (OK) cells, was transformed with hOAT1. Among the organic anions examined, hippuric acid, para‐hydroxyhippuric acid, ortho‐hydroxyhippuric acid, indoxyl sulphate and indoleacetic acid showed a high affinity for hOAT1 expressed in the OK cells. Indoxyl sulphate and indoleacetic acid concentration‐dependently inhibited proliferation of the hOAT1‐transformed cells. The h.p.l.c. analysis demonstrated that cellular uptake of these organic anions was significantly elevated in hOAT1‐transformed cells. These organic anions also concentration‐dependently stimulated cellular free radical production. The degrees of inhibition of cell proliferation and the stimulation of free radical production induced by the organic anions were significantly higher in the hOAT1‐transformed cells than vector‐transformed cells. The stimulatory effect of indoxyl sulphate on free radical production was abolished by anti‐oxidants and probenecid. Less free radical production was observed in the hOAT1‐transformed cells treated with p‐hydroxyhippuric acid, o‐hydroxyhippuric acid compared with indoxyl sulphate and indoleacetic acid. Hippuric acid had little effect on free radical production. Organic anions present in the serum of patients with progressive renal disease may cause proximal tubular injury via hOAT1‐mediated uptake. The mechanism of cellular toxicity by these uraemic toxins involves free radical production. Thus, some uraemic toxins may directly promote progression of chronic renal disease. British Journal of Pharmacology (2002) 135, 555–563; doi:10.1038/sj.bjp.0704482
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hempel, S. L., Buettner, G. R., O’Malley, Y. Q., Wessels, D. A., & Flaherty, D. M. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00061-1 · Cited by 740
Cited by
Barreto, F. C., Barreto, D. V., Liabeuf, S., Meert, N., Glorieux, G., Temmar, M., Choukroun, G., Vanholder, R., & Massy, Z. A. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03980609 · Cited by 929
The Gut Microbiome, Kidney Disease, and Targeted Interventions
Ramezani, A., & Raj, D. S. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013080905 · Cited by 743
The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective
Nigam, S. K., Bush, K. T., Martovetsky, G., Ahn, S.-Y., Liu, H. C., Richard, E., Bhatnagar, V., & Wu, W. (2015) · Physiological Reviews · doi:10.1152/physrev.00025.2013 · Cited by 502
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target
Ramezani, A., Massy, Z. A., Meijers, B., Evenepoel, P., Vanholder, R., & Raj, D. S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.09.027 · Cited by 394
Drug transport by Organic Anion Transporters (OATs)
Burckhardt, G. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.010 · Cited by 357
Metadata
- Authors
- Motojima, M., Hosokawa, A., Yamato, H., Muraki, T., & Yoshioka, T.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2002-01
- Volume
- 135
- Issue
- 2
- Pages
- 555-563
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1974206688
- Cited by
- 115
- References
- 1
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.